Edition:
India

People: Bio-Techne Corp (TECH.OQ)

TECH.OQ on NASDAQ Stock Exchange Global Select Market

197.67USD
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
$197.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,598
52-wk High
$217.11
52-wk Low
$132.75

Higgins, John 

Mr. John L. Higgins is Independent Director of Bio-Techne Corporation. Mr. John Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals, Inc. since January 2007 and has been a member of Ligand’s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins has served as a director of numerous public and private companies. He graduated Magna Cum Laude with a bachelor’s degree from Colgate University. Among other attributes, skills and qualifications, the Board believes Mr. Higgins is qualified to serve as a Director of the Company due to his combination of biopharmaceutical business, accounting and finance experience as well as his executive management experience, particularly with public companies.

Basic Compensation

Total Annual Compensation, USD 87,500
Restricted Stock Award, USD 92,412
Long-Term Incentive Plans, USD --
All Other, USD 93,473
Fiscal Year Total, USD 273,385

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Baumgartner

308,385

Charles Kummeth

9,664,870

James Hippel

2,448,890

Brenda Furlow

1,218,200

David Eansor

1,591,280

Robert Gavin

1,374,490
As Of  30 Jun 2018